The company has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.
PPD announced on June 25, 2020 that it has expanded its laboratory test portfolio with five new molecular, serology, and functional assays for COVID-19 vaccine and therapy development programs.
According to a company press release, the molecular assays will use reverse transcriptase, polymerase chain reaction (RT–PCR), a system that helps diagnose diseases and give a measure of gene expression, to aid in detecting SARS-CoV-2 and pinpoint the number of infectious particles to determine viral load. The assays work to target spike proteins that are specific to SARS-CoV-2 and nucleocapsid proteins that are more common in the coronavirus family.
PPD has developed two enzyme-linked immunosorbent assays for vaccine trials to identify immunoglobulin G to full-length recombinant protein for spike and for nucleocapsid, the press release said. The company has also created a plate-based functional assay to find anti-spike antibodies in human serum that can avoid infection by disrupting the binding of angiotensin converting enzyme 2 (ACE2) to SARS-CoV-2 spike protein.
“PPD Laboratories is fully committed to helping our customers bring COVID-19 vaccines and therapies to fruition,” said Christopher Fikry, MD, executive vice-president of PPD Laboratories, in the press release. “The addition of these five assays to our test portfolio will enable us to expand our support of many important COVID-19 trials. We’ve also incorporated innovative measures so trials can start more quickly, run more efficiently, and conclude sooner.”
Source: PPD
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.